Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Bioanalysis ; 5(15): 1831-41, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23905857

ABSTRACT

This White Paper is focused on the technical aspects regarding quantifying pharmaceutically derived inorganic elements in biomatrices in support of GLP nonclinical and clinical studies using inductively coupled plasma (ICP) techniques. For decades ICP has been used in support of Environmental Protection Agency analyses and has more recently been applied for use in the pharmaceutical industry. Current bioanalytical method validation and sample analysis regulatory guidance applies to chromatographic platforms used for analysis of large- and small-molecule PK and TK assessments; however, it is not directly applicable to all aspects of various ICP techniques. Increasingly, quadrupole and high-resolution ICP-MS methods of analysis are being used to quantify inorganic elements contained in pharmaceutical compounds and biomatrices. Many elements occur endogenously in biomatrices, affecting quantification of blanks, standard curve samples, QC samples, and the selection of appropriate levels for the LLOQ.


Subject(s)
Drug Discovery/instrumentation , Drug Discovery/methods , Pharmaceutical Preparations/analysis , Spectrophotometry, Atomic/instrumentation , Spectrophotometry, Atomic/methods , Biomarkers/analysis , Biomarkers/blood , Biomarkers/cerebrospinal fluid , Biomarkers/urine , Calibration , Drug Discovery/standards , Elements , Guidelines as Topic , Limit of Detection , Pharmaceutical Preparations/blood , Pharmaceutical Preparations/cerebrospinal fluid , Pharmaceutical Preparations/urine , Quality Control , Reference Standards , Specimen Handling , Spectrophotometry, Atomic/standards , Validation Studies as Topic
2.
AAPS J ; 14(3): 523-9, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22566150

ABSTRACT

Nonclinical safety studies are required to follow applicable Good Laboratory Practice (GLP) regulations. Nonclinical dose formulations are required to be analyzed to confirm the analyte concentration, homogeneity, and stability. Analytical samples that fall outside of the acceptance criteria are considered out of specification (OOS), and an investigation should be conducted. The US FDA has issued a guidance document for GMP studies on conducting OOS investigations. However, no regulatory guidance has been issued regarding nonclinical safety study (GLP) OOS investigations, which often vary in regard to content, assessment, and impact statements. There is opportunity to improve the quality of OOS investigations by defining expectations and providing guidance in several areas including root cause assessment, impact statements, and acceptable paths forward. This paper will provide recommendations of best practices for nonclinical dose formulation OOS investigations.


Subject(s)
Chemistry, Pharmaceutical , United States , United States Food and Drug Administration
3.
AAPS J ; 12(4): 628-34, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20711763

ABSTRACT

Nonclinical dose formulation analysis methods are used to confirm test article concentration and homogeneity in formulations and determine formulation stability in support of regulated nonclinical studies. There is currently no regulatory guidance for nonclinical dose formulation analysis method validation or sample analysis. Regulatory guidance for the validation of analytical procedures has been developed for drug product/formulation testing; however, verification of the formulation concentrations falls under the framework of GLP regulations (not GMP). The only current related regulatory guidance is the bioanalytical guidance for method validation. The fundamental parameters for bioanalysis and formulation analysis validations that overlap include: recovery, accuracy, precision, specificity, selectivity, carryover, sensitivity, and stability. Divergence in bioanalytical and drug product validations typically center around the acceptance criteria used. As the dose formulation samples are not true "unknowns", the concept of quality control samples that cover the entire range of the standard curve serving as the indication for the confidence in the data generated from the "unknown" study samples may not always be necessary. Also, the standard bioanalytical acceptance criteria may not be directly applicable, especially when the determined concentration does not match the target concentration. This paper attempts to reconcile the different practices being performed in the community and to provide recommendations of best practices and proposed acceptance criteria for nonclinical dose formulation method validation and sample analysis.


Subject(s)
Chemistry, Pharmaceutical , Dosage Forms , Focus Groups , Pharmaceutical Vehicles
SELECTION OF CITATIONS
SEARCH DETAIL
...